Nina Lass1, Thomas Reinehr. 1. Department of Pediatric Endocrinology, Diabetes and Nutrition Medicine, Vestische Hospital for Children and Adolescents Datteln, University of Witten/Herdecke, Datteln, Germany.
Abstract
BACKGROUND: Treatment outcome depends largely on treatment adherence (TA). However, studies analyzing TA in chronic endocrine diseases are scarce and controversial in childhood. PATIENTS AND METHODS: We studied TA in 103 children treated subcutaneously with growth hormone (GH) and 97 children treated orally with thyroxin. TA was calculated based on the prescription refill rates. The number of GH injections was recorded by an autoinjector device in 23 children treated with GH. RESULTS: The correlation between recorded TA and calculated TA based on prescription refill rates was very good (p < 0.001, r = 0.83). TA was lower (p < 0.01) in pubertal children compared to prepubertal children and in children self-administering their medication compared to those whose drug was administered by their parents, both in GH- and thyroxin-treated children. Overall, 67% of the pubertal children treated with GH and 58% of the pubertal children treated with thyroxin missed at least 1 dose per week. TA was higher (p < 0.001) in children with thyroxin treatment compared to children treated with recombinant human GH (8 vs. 26% missed >3 doses/week). DISCUSSION: Puberty and self-administration of drugs were negative predictors of TA. Therefore, in puberty, prevention and treatment efforts should be undertaken to improve TA, especially when adolescents administer their drugs themselves.
BACKGROUND: Treatment outcome depends largely on treatment adherence (TA). However, studies analyzing TA in chronic endocrine diseases are scarce and controversial in childhood. PATIENTS AND METHODS: We studied TA in 103 children treated subcutaneously with growth hormone (GH) and 97 children treated orally with thyroxin. TA was calculated based on the prescription refill rates. The number of GH injections was recorded by an autoinjector device in 23 children treated with GH. RESULTS: The correlation between recorded TA and calculated TA based on prescription refill rates was very good (p < 0.001, r = 0.83). TA was lower (p < 0.01) in pubertal children compared to prepubertal children and in children self-administering their medication compared to those whose drug was administered by their parents, both in GH- and thyroxin-treated children. Overall, 67% of the pubertal children treated with GH and 58% of the pubertal children treated with thyroxin missed at least 1 dose per week. TA was higher (p < 0.001) in children with thyroxin treatment compared to children treated with recombinant human GH (8 vs. 26% missed >3 doses/week). DISCUSSION: Puberty and self-administration of drugs were negative predictors of TA. Therefore, in puberty, prevention and treatment efforts should be undertaken to improve TA, especially when adolescents administer their drugs themselves.
Authors: Yelena P Wu; David D Stenehjem; Lauri A Linder; Bin Yu; Bridget Grahmann Parsons; Ryan Mooney; Mark N Fluchel Journal: J Pediatr Oncol Nurs Date: 2017-11-30 Impact factor: 1.636
Authors: Carlo L Acerini; David Segal; Sherwin Criseno; Kei Takasawa; Navid Nedjatian; Sebastian Röhrich; Mohamad Maghnie Journal: Front Endocrinol (Lausanne) Date: 2018-11-22 Impact factor: 5.555
Authors: Jens Sandahl Christiansen; Philippe F Backeljauw; Martin Bidlingmaier; Beverly M K Biller; Margaret C S Boguszewski; Felipe F Casanueva; Philippe Chanson; Pierre Chatelain; Catherine S Choong; David R Clemmons; Laurie E Cohen; Pinchas Cohen; Jan Frystyk; Adda Grimberg; Yukihiro Hasegawa; Morey W Haymond; Ken Ho; Andrew R Hoffman; Jeff M P Holly; Reiko Horikawa; Charlotte Höybye; Jens Otto L Jorgensen; Gudmundur Johannsson; Anders Juul; Laurence Katznelson; John J Kopchick; K O Lee; Kuk-Wha Lee; Xiaoping Luo; Shlomo Melmed; Bradley S Miller; Madhusmita Misra; Vera Popovic; Ron G Rosenfeld; Judith Ross; Richard J Ross; Paul Saenger; Christian J Strasburger; Michael O Thorner; Haim Werner; Kevin Yuen Journal: Eur J Endocrinol Date: 2016-03-23 Impact factor: 6.664
Authors: Martina de Zwaan; Josefine Fischer-Jacobs; Martin Wabitsch; Thomas Reinehr; Stefanie Meckes-Ferber; Ross D Crosby Journal: Front Endocrinol (Lausanne) Date: 2020-02-25 Impact factor: 5.555